Ian Gan S, de Jongh Mariana, Kaplan Marshall M
Division of Gastroenterology, Tufts Medical Center, Boston, MA 02111, USA.
Dig Dis Sci. 2009 Oct;54(10):2242-6. doi: 10.1007/s10620-008-0613-3. Epub 2008 Dec 12.
Modafinil may be a potentially effective treatment for primary biliary cirrhosis (PBC)-related fatigue. About 42 patients were given a 3-day trial of 100-200 mg modafinil. Response was defined as increased energy, decreased somnolence and sleep requirements, and improved daily function. Patients with positive responses were continued indefinitely on the medication. During the initial trial period, 31 (73%) patients had complete response and continued to take the medication. Eleven (26%) had no response. In long-term follow-up (average 17.7 months), 25 (81%) patients continued to take 100-200 mg modafinil daily. Some required an increased dosage and some took the medication as needed. Four (12%) patients stopped the medication because of side-effects or reduced efficacy; one patient (3%) stopped due to medication cost and one (3%) due to resolution of fatigue. Side-effects included insomnia, nausea, nervousness, and headaches. Modafinil appears to be a safe, effective treatment for PBC-related fatigue.
莫达非尼可能是治疗原发性胆汁性肝硬化（PBC）相关疲劳的一种潜在有效疗法。约42例患者接受了为期3天的100 - 200毫克莫达非尼试验。反应定义为精力增加、嗜睡和睡眠需求减少以及日常功能改善。有阳性反应的患者持续无限期服用该药物。在初始试验期，31例（73%）患者有完全反应并继续服药。11例（26%）无反应。在长期随访（平均17.7个月）中，25例（81%）患者继续每日服用100 - 200毫克莫达非尼。一些患者需要增加剂量，一些患者按需服药。4例（12%）患者因副作用或疗效降低而停药；1例患者（3%）因药物费用停药，1例（3%）因疲劳缓解停药。副作用包括失眠、恶心、紧张和头痛。莫达非尼似乎是治疗PBC相关疲劳的一种安全、有效疗法。
